MONROVIA, Calif. April 19, 2012
In 2009 the two companies entered into a collaboration agreement that provided CSL with access to Xencor’s proprietary XmAb technology platform to enhance the antibody-dependent cell cytotoxicity (ADCC) function of CSL’s therapeutic antibodies. XmAb engineered high ADCC Fc domains have an improved capacity to recruit the immune system to target cancer cells, giving antibodies more tumor killing power. As part of the collaboration Xencor has granted CSL several commercial licenses to move product candidates incorporating XmAb technology into development and ultimately commercialization.
About XmAb® High ADCC technology
XmAb High ADCC technology can increase the potency of therapeutic antibodies by specifically engaging the body’s immune system against target antigen cells. Xencor’s proprietary suite of XmAb® Fc variants allows the selective improvement of antibody cytotoxic properties by enhancing antibody-dependent cell cytotoxicity (ADCC), phagocytosis and/or complement activation. Increased antibody potency has the potential to improve antibody efficacy in a variety of therapeutic areas, including oncology, infectious disease and autoimmune disorders.
About Xencor, Inc.
SOURCE Xencor, Inc.